Embarrassing & Frustrating: People with Type 1 Diabetes Talk About Using Glucagon
Emergency glucagon is a life-saving medication used to treat severe hypoglycemia (low blood sugar) in people with diabetes—particularly in those…
FDA Approves First Drug to Delay the Full Onset of Type 1 Diabetes
The FDA approval of teplizumab — brand name Tzield — was announced today on November 17, 2022 for use in people…
Research Review: Glucagon Options, Hypoglycemia, and Emotions
The T1D Exchange team has published an article in Current Diabetes Reports reviewing the current literature on glucagon usage and…
The Discovery of Insulin: Thank You, Science
This post was originally published on taylordenniswrites.com on April 21, 2021. The year 2021 marks the 100th anniversary of the discovery…
Recognizing 100 Years of Insulin
Today, millions of people around the world live with type 1 diabetes (T1D), including an estimated 1.6 million in the United States alone—all because…
Emily’s Story: Using Nasal Glucagon to Treat Severe Hypoglycemia
Emily Marcum was excited to take her parents, John and Andrea, on a 10-mile walking tour of Manhattan and Brooklyn…
Pharma and Medtech CEOs at JPMorgan 2020 Weigh in on Insulin Pricing, Supply Issues, and Innovation
Executives of the Big Three pharma companies involved in diabetes research, development, and manufacturing — Eli Lilly and Co., Novo Nordisk, and Sanofi — spoke publicly this week at JPMorgan’s 2020 Healthcare conference on issues related to insulin pricing and supply.
